Dyserection is the inability to maintain an erection sufficient for pleasurable sexual performance. Management of this disorder includes a person’s medical history, sexual history, and psychological history. There are many drugs available for the treatment of erectile dysfunction, which include both brand name drugs and generic drugs. It is a common medical disorder affecting mainly men over 40 years of age. Stress and mental health issues can make the problem worse, and physical and psychological issues can also cause erectile dysfunction.
Download Sample Research with Industry Information @ https://www.trendsmarketresearch.com/report/sample/3950
The global erectile dysfunction market was $ 417.1 million in 2018 and is expected to reach $ 4,812.6 million by 2025 at a CAGR of 2.25% during the forecast period.
Growth by region
North America dominated the global erectile dysfunction market, occupying over 42.6% of the total market share in 2018. The various factors driving the market growth are better access to erectile dysfunction treatments and reimbursement coverage for high penile post-implant surgeries. Europe is the second largest market while Asia-Pacific shows the fastest growth due to the rapid evolution of the healthcare sector and the presence of huge opportunities for the development of this market. However, the Middle East and Africa have the minimum market share due to the presence of poor and slow developing countries, especially in the African region. The Middle East holds the major share of the regional market due to well-developed technology and high expenditure.
Conductors and constraints
Growing awareness of the disease, the increasing willingness of patients to seek medical assistance for the management of the disease, and the increasing presence of favorable guidelines are driving growth. The global erectile dysfunction market is also seeing increasing demand for low cost generic drugs, especially in APAC countries such as India and China. The increased risk of sexually transmitted diseases, the reduction in insurance coverage for the treatment of erectile dysfunction, the growing threat of counterfeit drugs and the presence of social stigma in developing countries are factors limiting the rates of erectile dysfunction. penetration.
Direct purchase this market research report now @ https://www.trendsmarketresearch.com/checkout/3950/Single
Industry Trends and Updates
In January 2017, Eli Lilly Company was recognized as the Most Ethical Company in the World. Pfizer Inc., an American global pharmaceutical company based in New York in June 2017, acquired Neksium from AstraZeneca.